Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.
Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Creates a wholesale prescription drug importation program which complies with federal standards and regulations for the purpose of generating substantial savings for consumers.
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
This bill (S 8756) modifies the implementation timeline for a law allowing close friends to arrange body donations for medical purposes after a person's death. It changes the effective date so that the health commissioner can immediately begin implementing the law - rather than waiting 180 days - upon the bill's passage. This adjustment primarily affects individuals who wish to donate a deceased person's body for medical education or research, ensuring faster administrative readiness. The bill is procedural in nature, focusing solely on implementation timing, not the eligibility for body donations.
This bill changes the language in New York's Public Health Law by replacing the term "addict" with "person with substance use disorder" in sections governing medical treatment. It specifically affects healthcare practitioners who prescribe controlled substances for maintenance or detoxification treatment, ensuring they reference patients as "person with substance use disorder" instead of "addict" in legal documents. The key mechanism is a simple terminology update within existing prescribing provisions, aiming to use more clinical and less stigmatizing language. This change aligns with broader efforts to reduce stigma in healthcare communication.
Requires anti-bias training for every medical student, medical resident and physician assistant student in the state; requires the department of health to make an annual report on the implementation and effectiveness of such training.
Relates to requirements for medical professionals and health care facilities that provide medication to patients for medical aid in dying; extends the initial effectiveness of certain provisions relating thereto.
This bill establishes New York's "Medical Aid in Dying Act," allowing terminally ill adults (18+) with decision-making capacity to request and self-administer medication to end their life. To qualify, a patient must have a terminal illness confirmed by two physicians (the attending physician and a consulting physician) and make an informed decision after being fully informed of alternatives, risks, and outcomes. The process requires an oral request, a written request signed by the patient and witnessed by two non-conflicted adults (not relatives or beneficiaries), and includes the right to rescind the request at any time. The bill also mandates documentation, safe disposal of unused medication, and state reporting.
This bill allows licensed pharmacists to order and administer specific medical tests, including COVID-19, flu, RSV, strep throat, HbA1c, hepatitis C, and HIV tests, all authorized by the FDA. It directly affects pharmacists (expanding their clinical role) and patients (increasing access to convenient testing). The law requires tests to meet FDA authorization and federal "waiver" requirements, aligning pharmacists with qualified health professionals under existing public health law. The bill modifies prior 2022 legislation but includes a sunset provision, with most provisions set to expire on July 1, 2028.
